Home » Stocks » AGIO

Agios Pharmaceuticals, Inc. (AGIO)

Stock Price: $55.79 USD 0.69 (1.25%)
Updated May 7, 2021 4:00 PM EDT - Market closed
Market Cap 3.90B
Revenue (ttm) 116.10M
Net Income (ttm) 1.59B
Shares Out 69.54M
EPS (ttm) 22.93
PE Ratio 2.43
Forward PE 2.47
Dividend n/a
Dividend Yield n/a
Trading Day May 7
Last Price $55.79
Previous Close $55.10
Change ($) 0.69
Change (%) 1.25%
Day's Open 55.56
Day's Range 55.21 - 56.69
Day's Volume 529,317
52-Week Range 32.47 - 58.93

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Agios (AGIO) incurs wider-than-expected loss in the first quarter of 2021. The company fails to record revenues due to the sale of its oncology portfolio including Tibsovo.

1 week ago - Zacks Investment Research

Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of -6.50% and -100.00%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

1 week ago - Zacks Investment Research

– Data from ACTIVATE and ACTIVATE-T Phase 3 Studies of Mitapivat in Pyruvate Kinase (PK) Deficiency and Phase 2 Study of Mitapivat in Thalassemia Accepted for Presentation at EHA 2021 Virtual Congress –

1 week ago - GlobeNewsWire

Agios Pharmaceuticals (AGIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 weeks ago - Zacks Investment Research

CAMBRIDGE, Mass., April 15, 2021 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat genetically defined diseases, today announced that ...

3 weeks ago - GlobeNewsWire

Agios Receives $1.8 Billion in Upfront Cash to Focus on Accelerating and Expanding its Genetically Defined Disease Portfolio

1 month ago - GlobeNewsWire

Agios Pharmaceuticals (AGIO) reported earnings 30 days ago. What's next for the stock?

1 month ago - Zacks Investment Research

CAMBRIDGE, Mass., March 25, 2021 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat genetically defined diseases, today announced that ...

1 month ago - GlobeNewsWire

With the trading day more than halfway over, the broad markets recovered slightly from Thursday's downturn, with the exception of the Dow Jones industrial average.

Other stocks mentioned: ABNB, EDIT, CNP, DNLI, PTR, TREE, VYGR ...
2 months ago - 24/7 Wall Street

Agios' (AGIO) loss meets estimates in the fourth quarter of 2020 while revenues beat the same. Sale of leukemia drug, Tibsovo, rise both sequentially as well as year over year.

2 months ago - Zacks Investment Research

– In Partnership with the Sickle Cell Community Consortium, Agios Works to Address Educational Resource Gaps Caused by COVID-19 for Students with Sickle Cell Disease –

2 months ago - GlobeNewsWire

– Strong Commercial Execution for Second Full Year of TIBSOVO ® with Fourth Quarter Net Revenue of $39.1M and $121.1M for Full Year 2020 –

2 months ago - GlobeNewsWire

CAMBRIDGE, Mass., Feb. 23, 2021 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and genetically defined diseases, today announ...

2 months ago - GlobeNewsWire

Agios Pharmaceuticals (AGIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

CAMBRIDGE, Mass., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat cancer and genetically defined diseases, today annou...

2 months ago - GlobeNewsWire

– 37 Percent of Patients Treated with Mitapivat Achieved ≥33% Reduction in Transfusion Burden Compared to Individual Historical Transfusion Burden Standardized to 24 Weeks (1-Sided p=0.0002) –

3 months ago - GlobeNewsWire

– Supplemental New Drug Application Planned for Submission in Q1 2021 – – Supplemental New Drug Application Planned for Submission in Q1 2021 –

3 months ago - GlobeNewsWire

– Company Expects to File for Regulatory Approval for Mitapivat for the Treatment of Adults with Pyruvate Kinase (PK) Deficiency in the U.S. in Q2 2021 and in the EU in Mid-2021 –

3 months ago - GlobeNewsWire

CAMBRIDGE, Mass., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and genetically defined diseases, today announ...

4 months ago - GlobeNewsWire

Agios recently sold off its oncology business to Servier for $2B ($1.8B in cash) creating a unique situation to buy a company with a strong drug development track record. With 2 drug approvals under its...

4 months ago - Seeking Alpha

Investors need to pay close attention to Agios (AGIO) stock based on the movements in the options market lately.

4 months ago - Zacks Investment Research

Agios (AGIO) sells its oncology business unit to French company Servier for around $2 billion. The company plans to solely focus on developing treatments for genetically defined diseases.

4 months ago - Zacks Investment Research

Agios' newly revamped business strategy is an extreme departure from the company's original mission, but it's a great deal for shareholders.

4 months ago - The Motley Fool

Investors applauded the company's planned sale of its oncology portfolio.

4 months ago - The Motley Fool

The announcement that Agios Pharmaceuticals Inc. (NASDAQ: AGIO) will be streamlining its portfolio sent shares sharply higher early Monday.

4 months ago - 24/7 Wall Street

Shares of Agios Pharmaceuticals Inc. soared 20.6% in premarket trading on Monday after the company said it is selling its oncology portfolio to Servier, a privately held French pharmaceutical company. S...

4 months ago - Market Watch

– Agios to Dedicate All Resources to Advancing Mitapivat as a Potential Treatment for Three Initial Hemolytic Anemias and Building on its Scientific Expertise in Cellular Metabolism and PK Activation to...

4 months ago - GlobeNewsWire

– Treatment with Mitapivat Induced Hemoglobin Increase of ≥1.0 g/dL in 6 of 11 (55%) Efficacy Evaluable Patients , Decreased Markers of Hemolysis, Reduced 2,3-DPG and Increased ATP –

5 months ago - GlobeNewsWire

Agios Pharmaceuticals (AGIO) reported earnings 30 days ago. What's next for the stock?

5 months ago - Zacks Investment Research

Agios' (AGIO) phase III ACTIVATE study evaluating mitapivat for addressing PK deficiency in patients with no regular blood transfusions achieves the primary goal.

5 months ago - Zacks Investment Research

CAMBRIDGE, Mass., Nov. 30, 2020 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced the...

5 months ago - GlobeNewsWire

CAMBRIDGE, Mass., Nov. 25, 2020 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced tha...

5 months ago - GlobeNewsWire

The FDA confers an orphan drug status on Agios' (AGIO) pyruvate kinase-R activator mitapivat for addressing sickle cell disease. Stock climbs in after-hours trading.

5 months ago - Zacks Investment Research

CAMBRIDGE, Mass., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced th...

5 months ago - GlobeNewsWire

Agios' (AGIO) earnings and revenues fall shy of estimates in the third quarter. The company lifts the lower end of 2020 sales guidance for its leukemia drug Tibsovo.

6 months ago - Zacks Investment Research

Agios Pharmaceuticals' (AGIO) CEO Jackie Fouse on Q3 2020 Results - Earnings Call Transcript

6 months ago - Seeking Alpha

  Shares of Agios Pharmaceuticals (NASDAQ:AGIO) were unchanged after the company reported Q3 results.

6 months ago - Benzinga

– Third Quarter TIBSOVO® Net Revenue of $31.7 Million; Company Narrows 2020 TIBSOVO® Net U.S. Revenue Guidance to $113–115 Million –

6 months ago - GlobeNewsWire

Company to Host Virtual Investor Event and Webcast on Tuesday, December 8, 2020 at 8:00 a.m. ET Company to Host Virtual Investor Event and Webcast on Tuesday, December 8, 2020 at 8:00 a.m. ET

6 months ago - GlobeNewsWire

CAMBRIDGE, Mass., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced tha...

6 months ago - GlobeNewsWire

Agios Pharmaceuticals (AGIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

6 months ago - Zacks Investment Research

Agios Pharmaceuticals (AGIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

6 months ago - Zacks Investment Research

CAMBRIDGE, Mass., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced th...

6 months ago - GlobeNewsWire

Agios: A Look At Mitapivat In Anaemia, Its Backup Indication

6 months ago - Seeking Alpha

Agios (AGIO) withdraws the regulatory filing for Tibsovo in Europe, which was developed to treat relapsed/refractory acute myeloid leukemia in adult patients with a susceptible IDH1 mutation.

6 months ago - Zacks Investment Research

Agios: A Look At TIBSOVO In CC Patients

6 months ago - Seeking Alpha

– Agios Continues to Advance Two Phase 3 Combination Trials of TIBSOVO ® in Newly Diagnosed AML Patients –

6 months ago - GlobeNewsWire

Agios Pharmaceuticals (AGIO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

7 months ago - Zacks Investment Research

– Supplemental New Drug Application Planned f or Submission in Q1 2021 –

7 months ago - GlobeNewsWire

Andrew Hirsch to Depart Agios and Remain a Strategic Advisor through October 2020 Andrew Hirsch to Depart Agios and Remain a Strategic Advisor through October 2020  

7 months ago - GlobeNewsWire

About AGIO

Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers TIBSOVO (ivosidenib), an oral targeted inhibitor for treating adult patients with relapsed or refractory acute myeloid leukemia (R/R AML), as well as to treat patients with newly diagnosed AML; and IDHIFA (enasidenib), an oral targeted inhibitor for patients with R/R AML and an isocitrate dehydrogenase 2 mutation. It is also developing TIBSOVO, which... [Read more...]

Industry
Biotechnology
IPO Date
Jul 24, 2013
CEO
Jacqualyn Fouse
Employees
562
Stock Exchange
NASDAQ
Ticker Symbol
AGIO
Full Company Profile

Financial Performance

In 2020, AGIO's revenue was $203.20 million, an increase of 72.33% compared to the previous year's $117.91 million. Losses were -$327.37 million, -20.44% less than in 2019.

Financial Statements

Analyst Forecasts

According to 12 analysts, the average rating for AGIO stock is "Buy." The 12-month stock price forecast is 64.88, which is an increase of 16.29% from the latest price.

Price Target
$64.88
(16.29% upside)
Analyst Consensus: Buy